Spleen and kidney deficiency type patients with myasthenia gravis the establishment of two-dimensional electrophoresis map and analysis of.docVIP

 PAGE \* MERGEFORMAT 17 Spleen and kidney deficiency type patients with myasthenia gravis the establishment of two-dimensional electrophoresis map and analysis of [Abstract] the establishment of spleen and kidney deficiency type myasthenia gravis in patients with two-dimensional polyacrylamide gel electrophoresis to observe the spleen and kidney deficiency type myasthenia gravis patients with normal serum protein expression differences. Methods: The serum protein extraction repeated freeze-thaw method to optimize the separation of the two-dimensional electrophoresis of serum proteins, the establishment of spleen and kidney deficiency type myasthenia gravis patients with normal two-dimensional polyacrylamide gel electrophoresis of serum, using two-dimensional polyacrylamide gel electrophoresis dedicated software on income the results of pattern analysis. Using matrix-assisted laser desorption ionization - time of flight mass spectrometry of the target protein between the two groups received points identified by mass spectrometry. Results: Two-dimensional electrophoresis, the establishment of two-dimensional polyacrylamide gel electrophoresis of serum, select a clear difference for the 21 protein spots identified by mass spectrometry, identified a total of eight kinds of proteins. Conclusion: proteomic techniques to quickly build virtual spleen and kidney in patients with myasthenia gravis serum protein expression profiling and mass spectrometry, for further studies on its pathogenesis and treatment of means of providing an experimental basis. [Keywords:] myasthenia gravis; protein group; electrophoresis; acetylcholine receptor Myasthenia gravis (myasthenia gravis, MG) mainly by the acetylcholine receptor (acetylcholine receptor, AchR) antibody-mediated, complement involvement dependent cell-mediated immunity against neuromuscular junction at postsynaptic membrane acetylcholine receptor in autoimmune disease. For the treatment of MG is still a lack of effect